Cargando…

PB1861: EFFICACY AND TOXICITY OF VENETOCLAX PLUS HYPOMETHYLATING AGENTS IN THE REAL LIFE OF ACUTE MYELOID LEUKEMIA

Detalles Bibliográficos
Autores principales:	Martini, Gianluca, Zappasodi, Patrizia, Ferretti, Virginia Valeria, Calabretta, Ludovica, Gelli, Eleonora, Cabrera, Claudia Patricia Tobar, Rossi, Marianna, Roncoroni, Elisa, Arcaini, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429947/ http://dx.doi.org/10.1097/01.HS9.0000974280.90440.f4

Ejemplares similares

PB1823: THE BONE MARROW MICROENVIRONMENT IN ACUTE MYELOID LEUKEMIA: THE ROLE OF MESENCHYMAL STEM CELLS AND THEIR IMPACT ON THE CLINICAL OUTCOME
por: Calabretta, Ludovica, et al.
Publicado: (2023)

Pharmacokinetics of Venetoclax Co-Administered with Posaconazole in Patients with Acute Myeloid Leukemia
por: De Gregori, Simona, et al.
Publicado: (2023)

PB1900: COMBINED TREATMENT WITH VENETOCLAX PLUS HYPOMETHYLATING AGENT OR CYTARABINE VERSUS TREATMENT WITH HYPOMETHYLATING AGENT ALONE IN ACUTE MYELOID LEUKEMIA IN POOR PROGNOSIS PATIENTS.
por: Saavedra, Minerva Montalvo, et al.
Publicado: (2023)

PB1846: MANAGEMENT OF PATIENTS TREATED WITH VENETOCLAX WITH HYPOMETHYLATING AGENTS: LONG-TERM INCIDENCE OF CYTOPENIAS AND INFECTIONS
por: Guardia-Torrelles, Ares, et al.
Publicado: (2023)

PB1872: SELINEXOR IN COMBINATION WITH VENETOCLAX AND HYPOMETHYLATING AGENTS FOR ACUTE MYELOID LEUKEMIA PATIENTS WITH SEVERE CO-MORBIDITIES
por: Chen, Fangli, et al.
Publicado: (2023)

PB1861: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
por: Byalik, T., et al.
Publicado: (2022)

PB1860: HIGH EFFICACY OF HYPOMETHYLATING AGENTS PLUS VENETOCLAX COMBINATION THERAPY IN ELDERLY PATIENTS AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY: A REAL-LIFE EXPERIENCE.
por: Zannier, Maria Elena, et al.
Publicado: (2023)

PB1906: HYPOMETHYLATING AGENT PLUS LOW DOSE VENETOCLAX – A CHEMOTHERAPY-FREE INDUCTION OF ACUTE MYELOID LEUKEMIA TO ACHIEVE COMPLETE REMISSION IN PATIENTS UNFIT FOR CHEMOTHERAPY
por: Kumar, Karthik, et al.
Publicado: (2023)

PB1840: OUTCOME OF ADULT ACUTE MYELOID LEUKEMIA PATIENTS WITH EXTRAMEDULLARY DISEASE AFTER TREATMENT WITH VENETOCLAX/HYPOMETHYLATING AGENTS
por: Kayser, Sabine, et al.
Publicado: (2023)

PB2413: SALVAGE THERAPY WITH VENETOCLAX AND A HYPOMETHYLATING AGENT FOR PATIENTS WITH AML RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
por: Shaforostova, Inna, et al.
Publicado: (2023)

PB1863: VENETOCLAX AND HYPOMETHYLATING AGENT BASED OUTPATIENT AML INDUCTION- COST-EFFECTIVE METHOD FOR LMICS-REAL WORLD DATA FROM A TERTIARY CARE CENTER
por: Chauhan, Priyanka, et al.
Publicado: (2023)

PB1840: MONOCENTRIC EXPERIENCE OF VENETOCLAX-BASED REGIMENS FOR ACUTE MYELOID LEUKEMIA
por: Sciumè, M., et al.
Publicado: (2022)

PB1893: CLONAL EVOLUTION WITH BCL-2 AMPLIFICATION DURING VENETOCLAX TREATMENT
por: Rodríguez-Afonso, Jorge, et al.
Publicado: (2023)

Enrichment of Double RUNX1 Mutations in Acute Leukemias of Ambiguous Lineage
por: Merati, Gabriele, et al.
Publicado: (2021)

PB1885: PHASE 1 STUDY OF ZIFTOMENIB IN COMBINATION WITH VENETOCLAX, VENETOCLAX/AZACITIDINE, OR STANDARD INDUCTION (7 + 3) CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
por: Zeidan, Amer M, et al.
Publicado: (2023)

PB1779: DEVELOPING NOVEL SYNERGISTIC DRUG COMBINATIONS WITH VENETOCLAX IN ACUTE MYELOID LEUKAEMIA
por: Harrigan, R., et al.
Publicado: (2022)

PB2168: BRUSATOL INDUCES APOPTOSIS IN AGGRESSIVE LYMPHOMA CELLS IN VITRO AND SYNERGIZES WITH VENETOCLAX
por: Szmyra, M., et al.
Publicado: (2022)

PB1862: VENETOCLAX AND AZACITIDINE THERAPY IN ACUTE MYELOID LEUKEMIA PATIENTS WITH SEVERE RENAL IMPAIRMENT
por: Naka, Ryosuke, et al.
Publicado: (2023)

PB1817: THE ADDITION OF ZALCITABINE TO ACUTE MYELOID LEUKEMIA TREATMENT MAY IMPROVE AZACITIDINE AND VENETOCLAX COMBINATION
por: Sofía, Álvarez-Galeano, et al.
Publicado: (2023)

PB1923: PATIENT AND PHYSICIAN CHARACTERISTICS ASSOCIATED WITH HYPOMETHYLATING AGENT USE IN HIGHER-RISK MYELODYSPLASTIC SYNDROMES
por: Zeidan, A., et al.
Publicado: (2022)

PB2353: HEALTHCARE RESOURCE UTILIZATION AND COSTS OFF THERAPY WITH FIXED-DURATION VENETOCLAX AMONG CLL PATIENTS
por: Allan, J. N., et al.
Publicado: (2022)

PB1877: EFFECTS OF VENETOCLAX-BASED COMBINATIONS FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA IN CLINICAL SETTINGS
por: Park, Young Seob, et al.
Publicado: (2023)

PB1886: REAL WORLD EXPERIENCE OF VENETOCLAX-AZACYTIDINE COMBINATION IN FRAIL ELDERLY PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY
por: Rahimi, Muhammad Naim Bin Che, et al.
Publicado: (2023)

PB1889: A CASE OF REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA INDUCED IMMUNE THROMBOCYTOPENIC PURPURA SUCCESSFULLY TREATED WITH VENETOCLAX
por: Yavuz, B., et al.
Publicado: (2022)

PB1795: MESENCHYMAL STROMAL CELL-DEPENDENT ADHESION PATHWAYS PROTECT AML CELLS FROM VENETOCLAX-INDUCED APOPTOSIS
por: Ciciarello, Marilena, et al.
Publicado: (2023)

PB1766: IN VITRO ACQUIRED RESISTANCE TO THE ORAL MYELOID KINASE INHIBITOR TUSPETINIB CREATES SYNTHETIC LETHAL VULNERABILITY TO VENETOCLAX
por: Sonowal, Himangshu, et al.
Publicado: (2023)

PB1736: CLINICAL ANALYSIS OF VENETOCLAX-BASED IN THE TREATMENT OF ADULT RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
por: LI, Jing, et al.
Publicado: (2023)

PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)
por: Mato, A. R., et al.
Publicado: (2022)

PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
por: Barrientos, J. C., et al.
Publicado: (2022)

PB1857: VENETOCLAX, AZACITIDINE, COMBINED WITH LOW-DOSE CYTARABINE IN OLDERLY OR UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
por: Han, Xiao, et al.
Publicado: (2023)

PB1757: NOVEL THERAPEUTIC STRATEGY TARGETING CELLULAR REDOX SYSTEMS USING DIMETHYL FUMARATE AND VENETOCLAX IN ACUTE MYELOID LEUKEMIA
por: Kawaguchi, Shin-Ichiro, et al.
Publicado: (2023)

PB1753: SYNERGISTIC ANTITUMOR EFFECT OF CHIDAMIDE WITH VENETOCLAX IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BY SUPPRESSING PI3K/AKT SIGNALING
por: Song, D., et al.
Publicado: (2022)

PB1905: REAL-WORLD EXPERIENCE OF LOW-DOSE VENETOCLAX WITH AZACITIDINE FOR UNFIT AML PATIENTS(≥60Y) WITH LOW LEUKOCYTE COUNT
por: Wei, Wenjian, et al.
Publicado: (2023)

PB1792: REPURPOSING OF ANTIBIOTICS INHIBITING MITOCHONDRIAL TRANSLATION IN COMBINATION WITH VENETOCLAX IN ACUTE MYELOID LEUKEMIA: FROM PRECLINICAL MODELS TO CLINICAL PRACTICE
por: Amato, Viviana, et al.
Publicado: (2023)

PB1865: SINGLE-COUNTRY, MULTICENTER, RETROSPECTIVE, OBSERVATIONAL, DESCRIPTIVE COHORT STUDY OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH VENETOCLAX IN ARGENTINA (VENARG).
por: Pagano Vilar, C., et al.
Publicado: (2022)

PB1925: VENETOCLAX IN COMBINATION WITH AZACITIDINE OR LOW-DOSE CYTARABINE IN PATIENTS WITH HIGH-RISK MDS AND AML - EXPERIENCE OF A CZECH HAEMATOLOGY CENTRE.
por: Minarik, L., et al.
Publicado: (2022)

PB1938: REAL WORLD EFFECTIVENESS AND SAFETY OF VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN TREATMENT NAIVE CLL PATIENTS – DATA FROM THE OBSERVATIONAL STUDY VERVE
por: Schwaner, Ingo, et al.
Publicado: (2023)

PB2005: AZACITIDINE IN COMBINATION WITH 14-DAY VENETOCLAX VERSUS AZACITIDINE MONOTHERAPY FOR MYELODYSPLASTIC SYNDROME WITH INCREASED BLASTS-2 IN CLINICAL PRACTICE SETTING
por: Žučenka, Andrius, et al.
Publicado: (2023)

PB1784: CLADRIBINE SYNERGIZES THE EFFECT OF VENETOCLAX ON CELL PROLIFERATION ARREST AND APOPTOSIS BY TARGETING DNA-PKCS/C-MYC SIGNALING IN ACUTE MYELOID LEUKEMIA
por: Hou, Yue, et al.
Publicado: (2023)

PB1821: COMBINATION OF BCL-2 INHIBITOR, HYPOMETHYLATION AGENTS AND LOW-DOSE CYTARABINE AS A SALVAGE THERAPY FOR ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES
por: Gao, X.-N., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1irgjfp1ptm7ju1sah5q4542ik